Stohr B - Search Results

1

Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.

Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR. Leapman MS, et al. Among authors: stohr b. Eur Urol. 2018 Nov;74(5):668-675. doi: 10.1016/j.eururo.2018.08.020. Epub 2018 Sep 1. Eur Urol. 2018. PMID: 30181067

2

Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.

Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Leapman MS, et al. Eur Urol. 2017 May;71(5):750-759. doi: 10.1016/j.eururo.2016.11.032. Epub 2016 Dec 9. Eur Urol. 2017. PMID: 27940155

3

Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study.

Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, Federman S, Vankalakunti M, Koo J, Bose S, Peralta-Venturina M, Ziffle JV, Grenert JP, Miller S, Chiu C, Amin MB, Simko JP, Stohr BA, Luthringer DJ. Sirohi D, et al. Among authors: stohr ba. Mod Pathol. 2018 Sep;31(9):1429-1441. doi: 10.1038/s41379-018-0065-z. Epub 2018 May 15. Mod Pathol. 2018. PMID: 29765141 Free article.

4

Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer.

Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, Simko JP. Greenland NY, et al. J Urol. 2019 Jul;202(1):90-95. doi: 10.1097/JU.0000000000000175. Epub 2019 Jun 7. J Urol. 2019. PMID: 30810466

5

TP53 structural variants in metastatic prostatic carcinoma.

Sirohi D, Devine P, Grenert JP, van Ziffle J, Simko JP, Stohr BA. Sirohi D, et al. PLoS One. 2019 Jun 19;14(6):e0218618. doi: 10.1371/journal.pone.0218618. eCollection 2019. PLoS One. 2019. PMID: 31216325 Free PMC article.

6

Pathophysiology, Clinical Manifestations, and Treatment of Lichen Sclerosus: A Systematic Review.

Fergus KB, Lee AW, Baradaran N, Cohen AJ, Stohr BA, Erickson BA, Mmonu NA, Breyer BN. Fergus KB, et al. Among authors: stohr ba. Urology. 2020 Jan;135:11-19. doi: 10.1016/j.urology.2019.09.034. Epub 2019 Oct 9. Urology. 2020. PMID: 31605681 Free article.

7

Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4.

Greenland NY, Cowan JE, Zhang L, Carroll PR, Chan E, Stohr BA, Simko JP. Greenland NY, et al. Prostate. 2020 May;80(8):653-659. doi: 10.1002/pros.23977. Epub 2020 Mar 27. Prostate. 2020. PMID: 32220141

8

Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category.

Greenland NY, Cowan JE, Chan E, Carroll PR, Stohr BA, Simko JP. Greenland NY, et al. Prostate. 2020 Dec;80(16):1421-1428. doi: 10.1002/pros.24072. Epub 2020 Sep 18. Prostate. 2020. PMID: 32946625

9

Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis.

Chen CV, Croom NA, Simko JP, Stohr BA, Chan E. Chen CV, et al. Hum Pathol. 2022 Jan;119:85-93. doi: 10.1016/j.humpath.2021.11.003. Epub 2021 Nov 17. Hum Pathol. 2022. PMID: 34800526 Free article.

10

Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer.

Greenland NY, Cooperberg MR, Wong AC, Chan E, Carroll PR, Simko JP, Stohr BA. Greenland NY, et al. Investig Clin Urol. 2022 Jan;63(1):27-33. doi: 10.4111/icu.20210262. Investig Clin Urol. 2022. PMID: 34983120 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters